skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon
Over the last few decades, there have been steady improvements in the prognosis of patients suffering from cystic fibrosis. This momentum is expected to continue, thanks to a new class of revolutionary CFTR-targeting therapies, which have the potential to increase life expectancy beyond the current average of 37 years.

Find out more about:

• The prevalence of cystic fibrosis in the US and five major EU markets

• The cystic fibrosis market value forecast from 2016 to 2025

• The compound annual growth rate in the cystic fibrosis market

This infographic will not be complimentary for long, so please make use of the opportunity to access the most cutting-edge information on cystic fibrosis.